IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls

Ironwood Pharmaceuticals, Inc. (IRWD) announced that it has initiated the rolling new drug application (“NDA”) submission for the next-generation GLP-2 analog, apraglutide, for treating short bowel syndrome (“SBS”) patients who are dependent on parenteral support.The NDA filing is expected to be completed in the third quarter of 2025.The company also announced a corporate restructuring and a strategic reorganization. IRWD has decided to reduce its current workforce by almost 50% to achieve long-term growth. ...